Description
Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for MDCK Cells (Kidney Cells, CCL-34)
- A biodegradable polymer based transfection reagent – once inside the cell, the polymer degrades into smaller less toxic components reducing cell toxicity, facilitating release of the transgene, and improving transfection efficiency
- High transfection efficiency of both siRNA and plasmid DNA without compromising cell viability
- Achieve robust siRNA uptake for dependable gene silencing
- Effective transfection under conditions of up to 40% serum
- Transfection kit includes Transfection Enhancer reagent
- Download MDCK transfection protocol: [PDF]
- Download MDCK CRISPR/Cas9 transfection protocol: [PDF]
- Download PowerPoint presentation for MDCK cells transfection kit: [PPT]
- Developed and manufactured by Altogen Biosystems
Transfection Efficiency:
Reagent exhibits at least 73% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems MDCK Transfection Protocol: [PDF]
Download MSDS: [PDF]
MDCK Cell Line:
The epithelial cell line Madin-Darby Canine Kidney (MDCK) was derived from the kidney cells of an adult cocker spaniel (Canis familiaris) in 1958 and is positively tested for keratin by immunoperoxidase staining. This is a model mammalian cell line extensively employed in biomedical research. MDCK cells are useful for processing of beta-amyloid precursor protein and its products. MDCK cells are susceptible to viral infection but make good transfection host. These cells could be helpful in studying kidney cells function and gene expression for biomedical research purposes. Furthermore, the MDCK cell line is widely used in influenza studies. MDCK cells are hyperdiploid with a bi-modal chromosome number distribution. Most spreads comprise one normal X chromosome, but there are no consistent identifiable marker chromosomes. Altogen Biosystems produces polymer-based transfection reagent kits for the MDCK cell line.
Data:
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into MDCK cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Figure 2. Protein expression of Lamin A/C in MDCK cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into MDCK cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
MDCK Transfection Reagent
Altogen Biosystems:
Altogen Biosystems provides pre-optimized transfection kits and electroporation products for life sciences and cancer research. Transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits (animal transfection): 1) Tissue-targeted reagents (delivery of proteins, DNA, and RNA into liver, pancreas, or kidney tissues), and 2) Broad range in vivo biodistribution reagents (PEG-Liposome based reagent, Nanoparticle-based in vivo reagent, Lipid-based transfection kit, and Polymer-based kit). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, mRNA, shRNA, siRNA, and other negatively charged biomolecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
Volume Options:
- 0.5 ml (Catalog #6845)
- 1.5 ml (Catalog #6846)
- 1.5 ml CRISPR (Catalog #2171)
- 8.0 ml (Catalog #7061)
